Abstract
A better understanding of sepsis-induced immunosuppression pathophysiology is desirable for the development of novel therapeutic strategies to prevent and reduce the rates of secondary infections and their associated mortality. Here we demonstrate that PD-L1+CD44+B220LowCD138+IgM+ regulatory plasma cells (PCs) are induced in a murine model of sepsis-induced immune alterations and in critically ill patients with bacterial sepsis and COVID-19. This was revealed both by detailed analysis of their phenotypical features and gene expression profile and by functional explorations comparing capacity of purified B cells and PCs to suppress T cell proliferation and IFNɣ secretion ex vivo. Sepsis-induced regulatory PCs exerted their suppressive function on T cells through IL-10 production and increased PD-L1 expression independently of regulatory T cells. Our findings thus reveal a novel pathophysiological mechanism of sepsis-induced immunosuppression that involves regulatory PCs. As such, these PCs constitute valid therapeutic targets to improve immune cell functions impaired by sepsis.
Competing Interest Statement
MM and EP are employees of bioMerieux SA, an in vitro diagnostic company. RC, MM, EP, CG, ACL, TR and GM work in a joint research unit, co funded by the Hospices Civils de Lyon and bioMerieux. This private company has no role in study design, results analysis or publication.
Funding Statement
REALISM study received funding from the Agence Nationale de la Recherche through a grant awarded to BIOASTER (Grant number #ANR 10 AIRT 03) and from bioMerieux, Sanofi and GSK. IMMUNOSEPSIS study was funded by Hospices civils de Lyon. RICO study was supported by funds from the Hospices Civils de Lyon, Fondation HCL and Claude Bernard Lyon 1 University / Region Auvergne Rhone-Alpes. CV is a recipient of a Poste d Accueil Inserm.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Adult patients from intensive care units (ICU) of academic hospital (Hospices Civils de Lyon, Lyon, France) enrolled in three observational clinical cohorts were studied either prospectively (RICO = REA IMMUNO COVID and IMMUNOSEPSIS 4 cohorts) or retrospectively (REALISM = REAnimation Low Immune Status Markers cohort). Samples in humans were collected under approved protocols registered under ClinicalTrials: NCT04392401 (RICO = REA IMMUNO COVID); NCT02638779 (REALISM cohort (REAnimation Low Immune Status Markers); NCT04067674 (IMMUNOSEPSIS 4). RICO clinical study was approved by ethics committee (Comite de Protection des Personnes Ile de France 1, IRB number/ IORG #: IORG0009918) under agreement number 2020-A01079-30. IMMUNOSEPSIS4 clinical study was approved by ethics committee (Comite de Protection des Personnes Ouest II, Angers Sud-Est II; RCB identification number: 2019-A000210-57, identification number SI/CPP: 19.01.23.71857), registered at the French Ministry of Research and Teaching (#DC 2008 509) and recorded at the Commission Nationale de l Informatique et des Libertes. REALISM clinical study was approved by ethics committee (Comite de Protection des Personnes Sud-Est II, Bron, France) and the French National Security agency for drugs and health-related products (Approval code: 69HCL15 0379, 30th November 2015).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# co-second to last authors
